{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:08:13Z","timestamp":1791547693287,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Plasmodium vivax<\/jats:italic> malaria is still an important public health problem in Ethiopia. Unlike <jats:italic>Plasmodium falciparum, P. vivax<\/jats:italic> has a dormant liver stage (hypnozoite) that can be a risk of recurrent vivax malaria unless treated by radical cure with primaquine. Drug resistance to chloroquine is threatening malaria control and elimination efforts. This study assessed the therapeutic efficacy and safety of chloroquine plus 14\u00a0days of primaquine on <jats:italic>P. vivax<\/jats:italic> infection based on parasitological, clinical, and haematological parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-arm in vivo prospective therapeutic efficacy study was conducted to assess the clinical and parasitological response to the first-line treatment of <jats:italic>P. vivax<\/jats:italic> in Ethiopia, chloroquine plus 14\u00a0days low dose of (0.25\u00a0mg\/kg\/day) primaquine between December 2022 and March 2023 at Hamusit Health Centre using the standard World Health Organization (WHO) protocol. A total of 100 study participants with <jats:italic>P. vivax<\/jats:italic> mono-infection who were over 6\u00a0months old were enrolled and monitored for adequate clinical and parasitological responses for 42\u00a0days. The WHO double-entry Excel sheet and SPSS v.25 software were used for Kaplan\u2013Meier survival analysis, and a paired t-test was used for analysis of haemoglobin improvements between follow up days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 100 patients were enrolled among those, 96% cases were rural residents, 93% had previous malaria exposure, and predominant age group was 5\u201315\u00a0years (61%). 92.6% (95% CI 85.1\u201396.4%) of enrolled patients were adequate clinical and parasitological response, and 7.4% (95% CI 3.6\u201314.9%) recurrences were observed among treated patients. The fever and parasite clearance rate on day 3 were 98% and 94%, respectively. The baseline haemoglobin levels improved significantly compared to those days 14 and 42 (p\u2009&lt;\u20090.001). No serious adverse event was observed during the study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, co-administration of chloroquine with primaquine was efficacious and well-tolerated with fast resolution of fever and high parasites clearance rate. However, the 7.4% failure is reported is alarming that warrant further monitoring of the therapeutic efficacy study of <jats:italic>P. vivax<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-024-05031-9","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T19:01:53Z","timestamp":1720292513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia"],"prefix":"10.1186","volume":"23","author":[{"given":"Habtamu","family":"Gebrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulat","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animen","family":"Ayehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussien","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henok","family":"Hailgiorgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Wuletaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesay","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"Tolera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremew","family":"Tasew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogess","family":"Kassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokretsion","family":"Gidey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"5031_CR1","unstructured":"WHO. World malaria report 2022. Geneva: World Health Organization. 2022."},{"key":"5031_CR2","unstructured":"WHO. World malaria report 2023. Geneva: World Health Organization. 2023."},{"key":"5031_CR3","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health, National malaria guidelines. Addis Ababa. 2017:1\u2013108."},{"key":"5031_CR4","unstructured":"PMI. Ethiopia Malaria Profile. Addis Ababa. 2022."},{"key":"5031_CR5","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National Malaria Elimination Strategic Plan: 2021\u20132025. Addis Ababa. 2020."},{"key":"5031_CR6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S1473-3099(14)70855-2","volume":"14","author":"RN Price","year":"2014","unstructured":"Price RN, Von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982\u201391.","journal-title":"Lancet Infect Dis"},{"key":"5031_CR7","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National malaria guidelines. Addis Ababa. 2018."},{"key":"5031_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-023-04562-x","volume":"22","author":"DA Mekonnen","year":"2023","unstructured":"Mekonnen DA, Abadura GS, Behaksra SW, Taffese HS, Bayissa GA, Bulto MG, et al. Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. Malar J. 2023;22:135.","journal-title":"Malar J"},{"key":"5031_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-3305-4-46","volume":"4","author":"T Ketema","year":"2011","unstructured":"Ketema T, Getahun K, Bacha K. Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethopia. Parasit Vectors. 2011;4:46.","journal-title":"Parasit Vectors"},{"key":"5031_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1471-4922(02)02249-3","volume":"18","author":"J-F Trape","year":"2002","unstructured":"Trape J-F, Pison G, Spiegel A, Enel C, Rogier C. Combating malaria in Africa. Trends Parasitol. 2002;18:224\u201330.","journal-title":"Trends Parasitol"},{"key":"5031_CR11","unstructured":"WHO Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization. 2009."},{"key":"5031_CR12","unstructured":"WHO. World Malaria Report 2018. Geneva, World Health Organization. 2018."},{"key":"5031_CR13","doi-asserted-by":"publisher","first-page":"e0277362","DOI":"10.1371\/journal.pone.0277362","volume":"18","author":"H Belay","year":"2023","unstructured":"Belay H, Alemu M, Hailu T, Mohammed H, Sime H, Hailegeorgies H, et al. Therapeutic efficacy of chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia. PLoS ONE. 2023;18:e0277362.","journal-title":"PLoS ONE"},{"key":"5031_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4269\/ajtmh.2007.76.203","volume":"76","author":"JL Goller","year":"2007","unstructured":"Goller JL, Jolley D, Ringwald P, Biggs B-A. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg. 2007;76:203\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5031_CR15","doi-asserted-by":"publisher","first-page":"101499","DOI":"10.1016\/j.tmaid.2019.101499","volume":"36","author":"S Xu","year":"2020","unstructured":"Xu S, Zeng W, Mbenda HGN, Liu H, Chen X, Xiang Z, Li C, Zhang Y, Baird JK, Yang Z. Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: a prospective open-label efficacy trial. Travel Med Infect Dis. 2020;36:101499.","journal-title":"Travel Med Infect Dis"},{"key":"5031_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1128\/AAC.04270-14","volume":"59","author":"L Yuan","year":"2015","unstructured":"Yuan L, Wang Y, Parker DM, Gupta B, Yang Z, Liu H, et al. Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. Antimicrob Agents Chemother. 2015;59:1230\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"5031_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1473-3099(18)30348-7","volume":"18","author":"RJ Commons","year":"2018","unstructured":"Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18:1025\u201334.","journal-title":"Lancet Infect Dis"},{"key":"5031_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4269\/ajtmh.18-0655","volume":"100","author":"E Mesa-Echeverry","year":"2019","unstructured":"Mesa-Echeverry E, Niebles-Bol\u00edvar M, Tob\u00f3n-Casta\u00f1o A. Chloroquine\u2013primaquine therapeutic efficacy, safety, and plasma levels in patients with uncomplicated Plasmodium vivax malaria in a Colombian Pacific region. Am J Trop Med Hyg. 2019;100:72\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"5031_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12936-015-0824-y","volume":"14","author":"K Rishikesh","year":"2015","unstructured":"Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et al. Therapeutic assessment of chloroquine\u2013primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J. 2015;14:310.","journal-title":"Malar J"},{"key":"5031_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.actatropica.2009.10.001","volume":"113","author":"AK Yeshiwondim","year":"2010","unstructured":"Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Trop. 2010;113:105\u201313.","journal-title":"Acta Trop"},{"key":"5031_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1128\/AAC.02050-12","volume":"57","author":"S Ganguly","year":"2013","unstructured":"Ganguly S, Saha P, Guha SK, Das S, Bera DK, Biswas A, et al. In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother. 2013;57:1246\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"5031_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20477724.2015.1133033","volume":"110","author":"K Rishikesh","year":"2016","unstructured":"Rishikesh K, Saravu K. Primaquine treatment and relapse in Plasmodium vivax malaria. Pathog Glob Health. 2016;110:1\u20138.","journal-title":"Pathog Glob Health"},{"key":"5031_CR23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1128\/CMR.00008-09","volume":"22","author":"JK Baird","year":"2009","unstructured":"Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508\u201334.","journal-title":"Clin Microbiol Rev"},{"key":"5031_CR24","doi-asserted-by":"publisher","first-page":"e35832","DOI":"10.7554\/eLife.35832","volume":"7","author":"I Rodriguez-Barraquer","year":"2018","unstructured":"Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife. 2018;7:e35832.","journal-title":"Elife"},{"key":"5031_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.47102\/annals-acadmedsg.V45N7p303","volume":"45","author":"H Subramony","year":"2016","unstructured":"Subramony H, Tangpukdee N, Krudsood S, Poovorawan K, Muangnoicharoen S, Wilairatana P. Evaluation of efficacy of chloroquine for Plasmodium vivax infection using parasite clearance times: a 10-year study and systematic review. Ann Acad Med Singap. 2016;45:303\u201314.","journal-title":"Ann Acad Med Singap"},{"key":"5031_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.actatropica.2017.02.027","volume":"171","author":"S Seifu","year":"2017","unstructured":"Seifu S, Zeynudin A, Zemene E, Suleman S, Biruksew A. Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia. Acta Trop. 2017;171:44\u201351.","journal-title":"Acta Trop"},{"key":"5031_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4269\/ajtmh.1964.13.237","volume":"13","author":"I McGregor","year":"1964","unstructured":"McGregor I. The passive transfer of human malarial immunity. Am J Trop Med Hyg. 1964;13:237\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"5031_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","volume":"16","author":"NJ White","year":"2017","unstructured":"White NJ. Malaria parasite clearance. Malar J. 2017;16:88.","journal-title":"Malar J"},{"key":"5031_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","volume":"31","author":"J Ducharme","year":"1996","unstructured":"Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet. 1996;31:257\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"5031_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s15010-021-01739-x","volume":"50","author":"MT Soe","year":"2022","unstructured":"Soe MT, Aung PL, Nyunt MH, Sein MM, Cho C, Yang Z, et al. Therapeutic efficacy of chloroquine for uncomplicated Plasmodium vivax malaria in southeastern and western border areas of Myanmar. Infection. 2022;50:681\u20138.","journal-title":"Infection"},{"key":"5031_CR31","doi-asserted-by":"publisher","first-page":"e01965","DOI":"10.1128\/AAC.01965-18","volume":"63","author":"S Ladeia-Andrade","year":"2019","unstructured":"Ladeia-Andrade S, Menezes MJ, de Sousa TN, Silvino ACR, de Carvalho Jr JF, Salla LC, et al. Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil. Antimicrob Agents Chemother. 2019;63:e01965-e11918.","journal-title":"Antimicrob Agents Chemother"},{"key":"5031_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.pt.2009.02.003","volume":"25","author":"NM Anstey","year":"2009","unstructured":"Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25:220\u20137.","journal-title":"Trends Parasitol"},{"key":"5031_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12936-015-1041-4","volume":"14","author":"S Getachew","year":"2015","unstructured":"Getachew S, Thriemer K, Auburn S, Abera A, Gadisa E, Aseffa A, et al. Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J. 2015;14:525.","journal-title":"Malar J"},{"key":"5031_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4269\/ajtmh.2003.68.410","volume":"68","author":"WE Collins","year":"2003","unstructured":"Collins WE, Jeffery GM, Roberts JM. A retrospective examination of anemia during infection of humans with Plasmodium vivax. Am J Trop Med Hyg. 2003;68:410\u20132.","journal-title":"Am J Trop Med Hyg"},{"key":"5031_CR35","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1128\/CDLI.8.6.1164-1170.2001","volume":"8","author":"V Nussenblatt","year":"2001","unstructured":"Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. Clin Diagn Lab Immunol. 2001;8:1164\u201370.","journal-title":"Clin Diagn Lab Immunol"},{"key":"5031_CR36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1086\/423140","volume":"190","author":"JN Waitumbi","year":"2004","unstructured":"Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA. Age-related changes in red blood cell complement regulatory proteins and susceptibility to severe malaria. J Infect Dis. 2004;190:1183\u201391.","journal-title":"J Infect Dis"},{"key":"5031_CR37","unstructured":"WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization. 2015."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-05031-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-05031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T19:02:30Z","timestamp":1720292550000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-05031-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5031"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-05031-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}